This week, KannAInsight features a new study on the effects of a cannabinoid-based drug, Nabilone, in lung cancer patients.
Over half of the patients diagnosed with advanced lung cancer experience anorexia. Nabilone is a synthetic cannabinoid that is approved by the FDA for the treatment of nausea and vomiting in treatment-resistant chemotherapy patients. Cannabinoid-based drugs, like Nabilone, have been recognized for their ability to improve appetite, yet clinical trials are needed to support their use in cancer patients.
In this recent clinical trial, patients treated with Nabilone for 8 weeks experienced increased appetite and carbohydrate intake. Notably, quality of life also showed significant improvement, including social and emotional functioning, pain, and insomnia.
Based on the results of this study, Nabilone has the potential to be a therapeutic option to aid in the treatment of cancer patients who are diagnosed with anorexia. Further research and larger trials are warranted to determine the efficacy of Nabilone for appetite in lung cancer patients.